A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans.
Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill.
Ozempic, which accounts for 41% of the company's sales, is an injectable anti-diabetic treatment that became wildly popular ...
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
They have also become increasingly popular after a number of celebrities began using Ozempic, which is primarily used to treat type 2 diabetes, to lose significant amounts of weight. In the UK, the ...
These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback